Personnel Information


UMEZAWA Yoshihiro

Job title

Assistant Professor

Graduating School 【 display / non-display

  • Hokkaido University, Faculty of Medicine, Graduated

Graduate School 【 display / non-display

  • Tokyo Medical and Dental University, Graduate School, Division of Medicine, Doctor's Course, 2017.03, Completed

Campus Career 【 display / non-display

  • 2018.04
    Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Medical and Dental Sciences, Advanced Therapeutic Sciences, Hematology, Assistant Professor
  • 2019.11
    Tokyo Medical and Dental University, Medical Hospital, Hospital Departments, Department of Internal Medicine, Hematology, Assistant Professor

Research Areas 【 display / non-display

  • Hematology


Published Papers & Misc 【 display / non-display

  • Masahide Yamamoto, Keisuke Tanaka, Yoshihiro Umezawa, Toshikage Nagao, Shigeo Toyota, Osamu Miura. Soluble Interleukin-2 Receptor Level at Diagnosis Predicts Prognosis of Patients With Follicular Lymphoma Irrespective of Initial Management Strategy. Anticancer Res.. 2019.09; 39 (9): 5115-5122. ( PubMed, DOI )

  • Kota Yoshifuji, Yoshihiro Umezawa, Ayako Ichikawa, Ken Watanabe, Osamu Miura, Masahide Yamamoto. Methotrexate-associated Classical Hodgkin Lymphoma Shows Distinct Clinicopathological Features but Comparable Clinical Outcomes With Sporadic Cases. In Vivo. 2019.09; 33 (5): 1599-1604. ( PubMed, DOI )

  • Akiyama Hiroki, Umezawa Yoshihiro, Ishida Shinya, Okada Keigo, Nogami Ayako, Miura Osamu. Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress CANCER LETTERS. 2019; 453 84-94. ( PubMed, DOI )

  • Umezawa Y, Kawamata N. Novel therapies for acute myeloid leukemia based on genomic aberrations The Japanese journal of clinical hematology. 2019; 60 (6): 594-599. ( PubMed, DOI )

  • Ayako Nogami, Keigo Okada, Shinya Ishida, Hiroki Akiyama, Yoshihiro Umezawa, Osamu Miura. Inhibition of the STAT5/Pim Kinase Axis Enhances Cytotoxic Effects of Proteasome Inhibitors on FLT3-ITD-Positive AML Cells by Cooperatively Inhibiting the mTORC1/4EBP1/S6K/Mcl-1 Pathway. Transl Oncol. 2018.11; 12 (2): 336-349. ( PubMed, DOI )

display all >>

Conference Activities & Talks 【 display / non-display

  • Ayako Nogami, Watanabe Daisuke, Keigo Okada, Hiroki Akiyama, Yoshihiro Umezawa, Toshikage Nagao, Shuji Tohdaand Osamu Miura. FLT3-ITD Enhances Proliferation and Survival of AML Cells through Activation of RSK1 to Upregulate the mTORC1/eIF4F Pathway Cooperatively with PIM or PI3K and to Inhibit Bad and Bim. 60th ASH Annual Meeting and Exposition 2019.12.01 FL, Orange County Convention Center

  • Yoshihiro Umezawa, ken Watanabe, Toshikage Nagao, Chizuko Sakashita, Ayako Nogami, Norihiko Kawamata, Osamu Miura, Masahide Yamamoto. Achieving deep molecular response after first-line TKI therapy for CML. The 80th annual meeting of the japanese society of hematology 2018.10.12 Osaka

  • Gaku Oshikawa, Yoshihiro Umezawa, Aiko Igarashi, Kazuhiko Kakihana, Kazuteru Ohashi, Norihiko Kawamata, Osamu MIura, Masahide Yamamoto. Impact of azacitidine for oligoblastic AML ineligible for stem cell transplantation. The 80th annual meeting of Japanese society of hematology 2018.10.12 Osaka

  • Hiroki Akiyama, Yoshihiro Umezawa, Keigo Okada, Shinya Ishida, Ayako Nogami, and Osamu Miura. Deubiquitinase Inhibitor WP1130 Blocks FLT3-ITD to Induce Apoptosis in Leukemic Cells. 59th ASH Annual Meeting & Exposition 2017.12.17 Atlanta, GA, USA

  • Tomoko Yamashita, Hiroki Tsutsumi, Kota Yoshifuji, Tatsuya Saito, Yoshihiro Umezawa, Ayako Nogami, Ken Watanabe, Toshikage Nagao, Chizduko Sakashita, Masahide Yamamoto, Ayako Arai, Norihiko Kawamata, Osamu Miura, Tetsuya Fukuda. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with 11q Deletion. 第79回日本血液学会学術集会 2017.10.22

display all >>